credence research inc n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Antibody Drug Conjugate Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023 PowerPoint Presentation
Download Presentation
Antibody Drug Conjugate Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023

Loading in 2 Seconds...

play fullscreen
1 / 3

Antibody Drug Conjugate Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023 - PowerPoint PPT Presentation


  • 3 Views
  • Uploaded on

According to the latest report published by Credence Research, Inc. “Antibody Drug Conjugate\nMarket– (Drug Type – Adcetris and Kadcyla): Market Growth, Future Prospects and Competitive\nAnalysis, 2016-2023,” the market was valued at USD 1.3 Bn in 2015

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Antibody Drug Conjugate Market- Growth, Share, Opportunities, Competitive Analysis, and Forecast 2016 – 2023' - amanj111


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
credence research inc

Credence Research Inc.

“Antibody Drug Conjugate Market- Growth, Share, Opportunities,

Competitive Analysis, and Forecast 2016 – 2023”

Buy Now

Sample Request

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web: http://www.credenceresearch.com

request sample

Request Sample

According to the latest report published by Credence Research, Inc. “Antibody Drug Conjugate

Market– (Drug Type – Adcetris and Kadcyla): Market Growth, Future Prospects and Competitive

Analysis, 2016-2023,” the market was valued at USD 1.3 Bn in 2015, and is expected to reach USD

29.3 Bn by 2022, expanding at a CAGR of 41.7% from 2016 to 2024.

Browse the full report Antibody Drug Conjugate Market: Market Growth, Future Prospects

and

Competitive

at http://www.credenceresearch.com/report/antibody-drug-conjugate-market

Market Insights

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs

such as chemotherapeutic drugs, radioactive isotopes, cytokines or cytotoxins via chemical linkers

with liable bonds. They combine the unique targeting property of monoclonal antibodies with the

cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased

tissues. Currently marketed drugs suffers from various stipulations like low potency, lack of

specificity and adverse effects. This has forced the pharmaceutical and research companies to

develop therapeutics that can overcome these barriers. Commercializing antibody drug conjugates

have overcome these scenarios and improve the medical conditions. The currently marketed antibody

drug conjugate drugs are Adcetris (Seattle Genetics) and Kadcyla (Genentech/Roche) followed by

several Antibody Drug Conjugates (ADCs) in pipeline showcase the potential for innovations in this

market.

In base year 2015, North America accounted for the largest market in the antibody drug conjugate

market due to the presence of major pharmaceutical companies working on the development of

antibody drug conjugate drugs. Moreover, one of the prime reason of North America’s dominance in

the antibody drug conjugates market is the fast-track approval and commercialization of ADCs in the

region as compared to other geographical regions. Europe held the second largest market for

antibody drug conjugates market. Kadcyla, one of the two drugs that are marketed currently is

manufactured by the Europe based pharmaceutical giant, Roche. Additionally, Europe was the second

region after where the commercialization of the ADCs were approved on a fast-track basis. Asia

pacific is anticipated to be the fastest growing segment in the antibody drug conjugate market due to

the approval of ADCs in Japan, China.

Market Competition Assessment:

The antibody drug conjugate market currently possesses only two companies having their drugs

marketed. However, many companies have their molecules in the clinical development stage which

hit market during the forecast period. The companies include Immunomedics, Spirogen, Pfizer,

Roche/Genentech, Oxford BioTherapeutics, and Others.

Analysis,

2016-2024

request sample 1

Request Sample

Browse the full Antibody Drug Conjugate Market - Growth, Future Prospects and Competitive Analysis,

2017 – 2025 report at http://www.credenceresearch.com/report/antibody-drug-conjugate-market

Latest Reports:

http://www.credenceresearch.com/report/vaccine-delivery-devices-market

http://www.credenceresearch.com/report/poly-alpha-olefin-pao-market

About:

Credence Research is a worldwide market research and counseling firm that serves driving organizations,

governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with

making enduring enhancements to their execution and understand their most imperative objectives. Over almost

a century, we've manufactured a firm extraordinarily prepared for this task.

Media Contact

Name: Chris Smith

Address: 105 N 1st ST #429,

SAN JOSE, CA 95103 US

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web: http://www.credenceresearch.com